ALLERGAN USA, INC. for ALLERGAN USA, INC.

Budget/Appropriations BUD

Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain.

Contacted: Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Access to appropriate mental health care treatments across the U.S. Creating access to Long Acting Reversible Contraceptives for patients in areas impacted by the Zika virus. Supporting investment in safe, quality, accessible, and affordable biopharma products. Ensuring level and appropriate penalties for those harming patients by illegally diverting and counterfeiting pharmaceutical products.

Contacted: Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE; Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES

Pharmacy PHA

Ensuring the safety of the drug supply chain to protect patients and keep Americans safe. Drug Compounding. Drug Importation/Counterfeit Drugs.

Contacted: HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); SENATE

Medical/Disease Research/Clinical Labs MED

Ensuring drug safety and efficacy gold standards at appropriate regulatory agency. Bioequivalence issues. Protecting patients from illegally diverted/counterfeited medicines.

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; Patent & Trademark Office (PTO)

Taxation/Internal Revenue Code TAX

Tax policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.

Foreign entity interest: Allergan plc, as the indirect parent of Allergan USA, Inc., has an interest to the extent that policy affects the tax treatment of its subsidiaries, foreign and domestic.

Contacted: Food & Drug Administration (FDA); SENATE; Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Trade (domestic/foreign) TRD

Promoting the Social Contract with patients to ensure they have affordable access to critical innovative medicines. Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation.

Contacted: Patent & Trademark Office (PTO); Food & Drug Administration (FDA); SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

Intellectual property protections for novel therapies to treat crucial medical needs. Patent reform proposals.

Contacted: Food & Drug Administration (FDA); SENATE; Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Medicare/Medicaid MMM

Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases.

Contacted: Centers For Medicare and Medicaid Services (CMS); Patent & Trademark Office (PTO); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES